Targeting DNA synthesis with the anti-metabolite cytarabine (NCT00022490, NCT00015834) has been first considered as a broad approach to counteract BCR-ABL-independent resistances in CML. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.